Non-Malignant Hematologic DisordersPhase 2NCT03615144
TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
A Phase 2 study testing Melphalan, Thiotepa and Clofarabine in people with Non-Malignant Hematologic Disorders, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
Trial summary
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease. Read more about this study
- Who is it for?
- Ages 1 year to 69 years
- Conditions the study is for
- Non-Malignant Hematologic Disorders
- What is being tested?
- Melphalan, Thiotepa and Clofarabine
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteUnited States
- Study dates
- 23 Jul 2018to 13 Nov 2020
- Phase
- Phase 2
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 69 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Subject Inclusion Criteria:
- Lethal disorders of Hematopoiesis correctable by transplant for which Alpha βeta T-cell and CD-19 depleted allogeneic hematopoietic stem cell transplantation is indicated including:
- Sickle cell disease (HbSS, HbSC, HbSB0 thalassemia, HbSB+, HbSD, HbSE) with at least one of the following criteria (Walters et al):
- Cerebrovascular accident lasting longer than 24 hours
- Impaired neuropsychological function with abnormal brain MRI/MRA
- Recurrent hospitalizations (>2 episodes/year over several years) or exchange transfusions for acute chest syndrome
- Recurrent priapism
- Stage I or II sickle chronic lung disease
- Sickle cell nephropathy (moderate to severe proteinuria or glomerular filtration rate 30-50% of predicted normal value for age)
- Bilateral proliferative retinopathy with major visual impairment in at least one eye
- Osteonecrosis of multiple joints
- Red cell alloimmunization during chronic transfusion therapy
- Thalassemia major with at least one of the following criteria:
- Age <16 years
- Available HLA-identical sibling
- Red blood cell transfusion dependency
- Lucarelli class 1 or 2 risk status (i.e. with only 0-2 of the following factors: hepatomegaly, portal fibrosis, or poor response to chelation therapy)
- Recurrence of disease after previous stem cell transplant
- Bone Marrow Failure Syndromes:
- Aplastic anemia refractory to immunosuppressive therapy
- Diamond Blackfan Anemia refractory to conventional therapy
- Shwachman-Diamond Syndrome
- Severe Congenital Neutropenia
- Congenital Amegakaryocytic Thrombocytopenia
- Thrombocytopenia Absent Radii syndrome
- Other marrow failure disorders not otherwise specified
- Autoimmune cytopenias refractory to all conventional treatments
- Autoimmune hemolytic anemia
- Immune thrombocytopenia
- Evan's syndrome
- Pure red cell aplasia
- Histiocytic disorders:
- Hemophagocytic lymphohistiocytosis
- High risk, recurrent or refractory Langerhans cell histiocytosis
- Secondary HLH
Subject Inclusion Criteria:
- Recipient's age birth to < 70 years old
- Patients must have adequate organ function measured by:
- Cardiac: asymptomatic or if symptomatic then LVEF at rest must be ≥ 50% and must improve with exercise.
- Hepatic: < 3x ULN AST and ≤ 1.5 mg/dl total serum bilirubin, unless there is congenital benign hyperbilirubinemia or if the hyperbilirubinemia is directly caused by the disease in which the patient is receiving a transplant for. Patients with higher bilirubin levels due to causes other than active liver disease are also eligible with PI approval e.g. patients with PNH, Gilbert"s disease or other hemolytic disorders.
- Pulmonary: asymptomatic or if symptomatic, DLCO ≥ 50% of predicted (corrected for hemoglobin).
- Renal: serum creatinine ≤1.5x normal for age. If serum creatinine is outside the normal range, then CrCl > 70 mL/min/1.73m2 (calculated or estimated) or GFR (mL/min/1.72m2) >30% of predicted normal for age.
- Normal GFR in Children and Young Adults.
Donor Inclusion Criteria:
- Each donor must meet criteria outlined by institutional guidelines and be medically eligible to donate according to NMDP (or equivalent donor search organization) criteria including testing for antibodies to Human TLymphotrophic Virus Types I \& II (Anti-HTLV-I/II) and screening for West Nile Virus, Creutzfeldt-Jakob disease and Zika.
- Pediatric donors should weigh ≥ 25.0 kg, have adequate peripheral venous catheter access for leukapheresis or must agree to placement of a central catheter.
- Donor should be healthy and agree to receive G-CSF followed by donation of peripheral blood stem cells.
- Donors must agree to anesthesia and marrow donation (in cases of inadequate PBSC collection).
- Related or unrelated donors who are 7/8 or 8/8 HLA-antigen matched for haplotypes A, B, C, DRB1 OR Related donors who are 4-6/8 HLA-antigen matched.
Subject Exclusion Criteria:
- Female patients who are pregnant or breast-feeding
- Active viral, bacterial or fungal infection
- Patient seropositive for HIV-I/II; HTLV-I/II
- Karnofsky (adult)/Lansky (pediatric) < 70%
- Inherited DNA repair deficiency: Fanconi Anemia and Dyskeratosis Congenita. These are presently undergoing transplantation based on a multi-center protocol
- Patients with Thalassemia major with Pesaro risk score >II
- Inherited metabolic disorders: Hurler Syndrome, Sly syndrome (MPSVIII), α-Mannosidosis, X- ALD, Osteopetrosis
Donor Exclusion Criteria:
- Donors who are seropositive for HIV-I/II or HTLV-I/II and female patients who are pregnant or breastfeeding will not be eligible for this study.
Trial locations and contacts
1 site in 1 country.
United States1 site
Memorial SloanKettering Cancer Center
New York, New York, 10065
About this study
Official title: A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.
- Conditions
- Non-Malignant Hematologic Disorders
- Being tested
- Melphalan, Thiotepa, Clofarabine, Fludarabine, Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)
- Keywords
- T-cell, B-cell, CliniMACS System, Melphalan, Thiotepa, Clofarabine, Fludarabine, 17-596
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
MelphalanDrug
Melphalan 70 mg/m2/day x 2
ThiotepaDrug
Thiotepa 7.5 mg/kg/day x 2
ClofarabineDrug
Clofarabine 20-30 mg/m2/day x 5
FludarabineDrug
Fludarabine 30 mg/m2/day x 5
Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)Drug
antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment.
CliniMACS reagentsProcedure or surgery
Products will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS.
| Study group | Role | What they receive |
|---|---|---|
| Melphalan/Thiotepa/Clofarabine | Active comparator | Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning. Receives: Drug: Melphalan; Drug: Thiotepa; Drug: Clofarabine; Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®); Procedure: CliniMACS reagents |
| Melphalan/Thiotepa/ Fludarabine | Active comparator | Melphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning. Receives: Drug: Melphalan; Drug: Thiotepa; Drug: Fludarabine; Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®); Procedure: CliniMACS reagents |
What is being measured
The primary outcome is the main question the study is designed to answer.
Overall Survival (OS)
Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.
Measured: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Aug 2018
- Study start23 Jul 2018
- Primary completion13 Nov 2020
- Study completion13 Nov 2020
Why it stopped: Participant accrual low and the study was closed
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Non-Malignant Hematologic DisordersStudies of the same condition, open and under way.
- More trials run by Memorial Sloan Kettering Cancer CenterThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Model description
- For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Maria Cancio, MD, Principal investigator, Memorial Sloan Kettering Cancer Center
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03615144
- Sponsor's protocol ID
- 17-596
- Status last verified
- Nov 2020
- First submitted
- 30 Jul 2018
- Last updated
- 24 Mar 2021
- Results posted
- Yes, on ClinicalTrials.gov
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Mar 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors
- ClinicalTrials.gov ID
- NCT03615144
- Acronym / sponsor ID
- 17-596
- Conditions
- Non-Malignant Hematologic Disorders
- Keywords
- T-cell, B-cell, CliniMACS System, Melphalan, Thiotepa, Clofarabine, Fludarabine, 17-596
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Participant accrual low and the study was closed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterUniversity, hospital or other
- Study start
- 23 Jul 2018 (actual)
- Primary completion
- 13 Nov 2020 (actual)
- Study completion
- 13 Nov 2020 (actual)
- First posted
- 3 Aug 2018 (actual)
- Results
- Posted 24 Feb 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to find out if removing a specific type of white blood cell (called alpha beta T-cell) that help make up the transplant donor's stem cells can improve results of blood stem cell transplant for the participant's disease.
Study design
- Primary purpose
- Treatment
- Allocation
- Non-randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
- Model description
- For this trial, patients will be assigned to receive one of two conditioning regimens, based on their disease, disease severity, organ status and history of red blood cell alloimmunization.
| Arm | Type | Receives |
|---|---|---|
| Melphalan/Thiotepa/Clofarabine | Active comparator | Drug: Melphalan, Drug: Thiotepa, Drug: Clofarabine, Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®), Procedure: CliniMACS reagentsMelphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Clofarabine 20-30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning. |
| Melphalan/Thiotepa/ Fludarabine | Active comparator | Drug: Melphalan, Drug: Thiotepa, Drug: Fludarabine, Drug: Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®), Procedure: CliniMACS reagentsMelphalan 70 mg/m2/day x 2, Thiotepa 7.5 mg/kg/day x 2 and Fludarabine 30 mg/m2/day x 5. Patients will also receive rabbit anti-thymocyte globulin at 2.5 mg/kg/day x 3 doses prior to the start of conditioning. |
Who may qualify
- Ages
- 1 year to 69 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| MelphalanMelphalan 70 mg/m2/day x 2 | Drug | Melphalan/Thiotepa/ Fludarabine, Melphalan/Thiotepa/Clofarabine |
| ThiotepaThiotepa 7.5 mg/kg/day x 2 | Drug | Melphalan/Thiotepa/ Fludarabine, Melphalan/Thiotepa/Clofarabine |
| ClofarabineClofarabine 20-30 mg/m2/day x 5 | Drug | Melphalan/Thiotepa/Clofarabine |
| FludarabineFludarabine 30 mg/m2/day x 5 | Drug | Melphalan/Thiotepa/ Fludarabine |
| Anti-Thymocyte Globulin (Rabbit) (Thymoglobulin®)antithymocyte globulin (ATG) (rabbit ATG 2.5 mg/kg/day x 3 or equine ATG 15 mg/kg/day x 3 (or 40 mg/kg/day x 1 equine ATG if rabbit ATG is not tolerated) during pre-transplant conditioning to deplete host T-cells that could hamper engraftment. | Drug | Melphalan/Thiotepa/ Fludarabine, Melphalan/Thiotepa/Clofarabine |
| CliniMACS reagentsProducts will then undergo TCR-αβ+ and CD-19 depletion using the CliniMACS. | Procedure or surgery | Melphalan/Thiotepa/ Fludarabine, Melphalan/Thiotepa/Clofarabine |
Primary outcome
Overall Survival (OS)
Time frame: 2 years
Overall survival is defined as time from transplant to death or last follow-up. Rate greater than 0.75 would be considered a success.
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Mar 2021.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Memorial Sloan Kettering Cancer CenterLink provided by the sponsor.
Related trials for Non-Malignant Hematologic Disorders
Enrolling by invitationObservational study
Collection of Tissue Specimens From Patients With Solid Tumors or Blood Disorders and Their HLA-Compatible Family Members
Neoplasms, Hematologic Neoplasms
RecruitingObservational study
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Chronic Myeloproliferative Disorders, Leukemia
RecruitingPhase 1/2
Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma
Lymphoma, Waldenström Macroglobulinemia (WM)
RecruitingPhase 2
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia
RecruitingPhase 2
AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion
Acute Leukemia, Severe Aplastic Anemia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Maria Cancio, MD principal investigator
Memorial Sloan Kettering Cancer Center
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Melphalan, Thiotepa and Clofarabine in people with Non-Malignant Hematologic Disorders, run by Memorial Sloan Kettering Cancer Center at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 24 Mar 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 24 Feb 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Overall Survival (OS) (time frame: 2 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Mar 2021.